Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the officials of the Company will participate in the following events for group and one-on-one meeting with investors: 1. J.P. Morgan India Investor Summit 2023 2. Kotak Healthcare Forum Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the officials of the Company will participate in the following events for group and one-on-one meeting with investors: 1. J.P. Morgan India Investor Summit 2023 2. Kotak Healthcare Forum Mankind Pharma Ltd - 543904 - Intimation About Change In Corporate Identification Number ('CIN') Of Mankind Pharma Limited ('The Company')
We hereby inform that pursuant to the listing of equity shares of the Company on BSE Limited and National Stock Exchange of India Limited on May 09, 2023 and based on our application made to the Registrar of Companies, NCT of Delhi and Haryana, the CIN of the Company has been changed from U74899DL1991PLC044843 to L74899DL1991PLC044843 in the records of the Ministry of Corporate Affairs, Government of India to reflect the listing status of the Company. The Company will update the new CIN wherever applicable in due course. You are requested to kindly update the CIN of the Company in your records and also in the Corporate Information section. Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and in compliance with various circulars issued by the Ministry of Corporate Affairs, we hereby enclose copies of newspaper advertisement published in "Financial Express" and "Jansatta" on August 29, 2023 regarding 32nd Annual General Meeting of the Company to be held on Friday, September 22, 2023 through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM") and information relating to e-voting. Mankind Pharma Ltd - 543904 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for F.Y. 2022-23 Mankind Pharma Ltd - 543904 - Reg. 34 (1) Annual Report.
Notice of 32nd Annual General Meeting along with copy of the Annual Report for F.Y. 2022-23 Mankind Pharma Ltd - 543904 - Notice Of Annual General Meeting To Be Held On September 22, 2023
Notice of 32nd Annual General Meeting along with copy of the Annual Report for F.Y. 2022-23 Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company in their meeting held today i.e. August 24, 2023 have approved the incorporation of a wholly owned subsidiary by the name Mankind Medicare Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with various circulars issued by the Ministry of Corporate Affairs, we hereby enclose copies of newspaper advertisement published in "Financial Express" and "Jansatta" on August 24, 2023 regarding ensuing Annual General Meeting of the Company to be held on Friday, September 22, 2023 through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") and information relating to e-voting. Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Investor Conference Call for Q1FY24 held on Thursday, August 03, 2023.